Patents by Inventor Clarisse Lorin

Clarisse Lorin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hepatitis B immunization regimen and compositions
    Patent number: 11957749
    Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 16, 2024
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Virginia Ammendola, Babak Bayat, Clarisse Lorin, Ventzislav Bojidarov Vassilev, Alessandra Vitelli
  • HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONS
    Publication number: 20210154290
    Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.
    Type: Application
    Filed: December 14, 2018
    Publication date: May 27, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Babak BAYAT, Clarisse LORIN, Ventzislav Bojidarov VASSILEV, Alessandra VITELLI
  • RECOMBINANT MEASLES VIRUSES EXPRESSING EPITOPES OF ANTIGENS OF RNA VIRUSES - USE FOR THE PREPARATION OF VACCINE COMPOSITIONS
    Publication number: 20210102220
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Application
    Filed: September 9, 2020
    Publication date: April 8, 2021
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic TANGY, Clarisse LORIN, Lucile MOLLET, Frederic DELEBECQUE
  • RECOMBINANT MEASLES VIRUSES EXPRESSING EPITOPES OF ANTIGENS OF RNA VIRUSES - USE FOR THE PREPARATION OF VACCINE COMPOSITIONS
    Publication number: 20210095315
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 1, 2021
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic TANGY, Clarisse LORIN, Lucile MOLLET, Frederic DELEBECQUE
  • HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONS
    Publication number: 20210069322
    Abstract: There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.
    Type: Application
    Filed: December 14, 2018
    Publication date: March 11, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Babak BAYAT, Clarisse LORIN, Ventzislav Bojidarov VASSILEV, Alessandra VITELLI
  • Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
    Patent number: 10793877
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: October 6, 2020
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIEQUE
    Inventors: Frederic Tangy, Clarisse Lorin, Lucile Mollet, Frederic Delebecque
  • RECOMBINANT MEASLES VIRUSES EXPRESSING EPITOPES OF ANTIGENS OF RNA VIRUSES - USE FOR THE PREPARATION OF VACCINE COMPOSITIONS
    Publication number: 20200095607
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 26, 2020
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic TANGY, Clarisse LORIN, Lucile MOLLET, Frederic DELEBECQUE
  • Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
    Patent number: 10519466
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: December 31, 2019
    Assignees: INSTlTUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFlQUE
    Inventors: Frederic Tangy, Clarisse Lorin, Lucile Mollet, Frederic Delebecque
  • RECOMBINANT MEASLES VIRUSES EXPRESSING EPITOPES OF ANTIGENS OF RNA VIRUSES - USE FOR THE PREPARATION OF VACCINE COMPOSITIONS
    Publication number: 20180195088
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Application
    Filed: February 9, 2018
    Publication date: July 12, 2018
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic TANGY, Clarisse LORIN, Lucile MOLLET, Frederic DELEBECQUE
  • Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
    Patent number: 9914937
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: March 13, 2018
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic Tangy, Clarisse Lorin, Lucile Mollet, Frederic Delebecque
  • RECOMBINANT MEASLES VIRUSES EXPRESSING EPITOPES OF ANTIGENS OF RNA VIRUSES - USE FOR THE PREPARATION OF VACCINE COMPOSITIONS
    Publication number: 20160040187
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Application
    Filed: March 24, 2015
    Publication date: February 11, 2016
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR
    Inventors: Frederic TANGY, Clarisse LORIN, Lucile MOLLET, Frederic DELEBECQUE
  • Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
    Patent number: 9012214
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, the recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against the RNA virus or against both measles virus and against the RNA virus. It also relates to the use of the recombinant measles virus for the preparation of immunogenic compositions.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: April 21, 2015
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Frédéric Tangy, Clarisse Lorin, Lucile Mollet, Frédéric Delebecque
  • HIV VACCINE
    Publication number: 20140234399
    Abstract: The present invention relates to immunogenic compositions comprising HIV-1 antigens and uses thereof in the prevention and/or treatment of HIV-1. In particular, the invention relates to the use of HIV-1 antigens from one clade in the prevention and/or treatment of disease associated with HIV-1 infection from a heterologous HIV-1 clade.
    Type: Application
    Filed: December 18, 2013
    Publication date: August 21, 2014
    Applicant: GlaxoSmithKline Biologicals, s.a.
    Inventors: Patricia BOURGUIGNON, Marguerite Christine Koutsoukos, Clarisse Lorin, Lisa McNally, Gerald Hermann Voss
  • RECOMBINANT MEASLES VIRUSES EXPRESSING EPITOPES OF ANTIGENS OF RNA VIRUSES - USE FOR THE PREPARATION OF VACCINE COMPOSITIONS
    Publication number: 20130052218
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Application
    Filed: February 4, 2010
    Publication date: February 28, 2013
    Inventors: Frédéric Tangy, Clarisse Lorin, Lucile Mollet, Frédéric Delebecque
  • Recombinant measles viruses expressing epitopes of antigens of RNA viruses - use for the preparation of vaccine compositions
    Publication number: 20060013826
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Application
    Filed: December 20, 2004
    Publication date: January 19, 2006
    Inventors: Frederic Tangy, Clarisse Lorin, Lucile Mollet, Frederic Delebecque